Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00736229 · ClinicalTrials.gov registry record · Phase 4

Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

A Phase 4 study, sponsored by Saint Luke's Health System.

Completed
Registry status
Phase 4
Development phase
40
Enrollment target

NCT00736229 is a Phase 4 study that has completed, run by Saint Luke's Health System. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00736229, a Phase 4 study, has completed, sponsored by Saint Luke's Health System.

COMPLETED
Registry status
Phase 4
Development phase
40 participants
Enrollment target

Study Summary

The purpose of this study is to determine the efficacy of intravenous Exenatide therapy in hyperglycemic patients admitted to the coronary intensive care unit.

Interventions

  • DRUG Exenatide

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2008-08
Est. Completion 2012-08
Phase Phase 4

Sponsor

Saint Luke's Health System

26 total trials

What the Registry Record Tells You About NCT00736229

The ClinicalTrials.gov registry entry for NCT00736229 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Saint Luke's Health System, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Exenatide is the first listed.

NCT00736229 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00736229 about?

NCT00736229 is a clinical study titled "Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients". The purpose of this study is to determine the efficacy of intravenous Exenatide therapy in hyperglycemic patients admitted to the coronary intensive care unit.

What is the current status of trial NCT00736229?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2008-08. Estimated completion is 2012-08.

What interventions are being tested in trial NCT00736229?

The interventions under investigation include: Exenatide (DRUG).

Who is sponsoring clinical trial NCT00736229?

This trial is sponsored by Saint Luke's Health System, which has 26 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.